AP
Publicaties op Oncologisch.com
INDUCE-3: A Gerandomiseerde Fase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent...
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide,...
Belantamab mafodotin plus pomalidomide-dexamethason bij myeloom: DREAMM-8 fase III